Skip to Main Content

Paper Details

A germline FANCA alteration that is associated with increased sensitivity to DNA damaging agents.
Cold Spring Harb Mol Case Stud
22
2017
DDR gene, FANC protein complex, FANCA, Fanconi anemia, S1088F, S1088F FANCA, S1088F FANCA mutant protein, S1088F FANCA variant, cisplatin, genes, germline, men, metastatic prostate cancer, metastatic, castrate-resistant prostate cancer, patient, patients, prostate cancer
Author NameAffiliation
David WilkesEnglander Institute for Precision Medicine, Weill Cornell Medicine and New York-Presbyterian Hospital
Verena Sailer
Hui XueUniversity of British Columbia
Hui XueUniversity of British Columbia
Colin C CollinsUniversity of British Columbia
Colin C CollinsUniversity of British Columbia
Martin E GleaveUniversity of British Columbia
Martin E GleaveUniversity of British Columbia
Yuzhuo WangUniversity of British Columbia
Yuzhuo WangUniversity of British Columbia
Francesca DemichelisUniversity of Trento
Francesca DemichelisUniversity of Trento
Himisha Beltran
Himisha BeltranSandra and Edward Meyer Cancer Center
Himisha Beltran
Himisha BeltranSandra and Edward Meyer Cancer Center
Mark A RubinEnglander Institute for Precision Medicine, Weill Cornell Medicine and New York-Presbyterian Hospital
Mark A RubinSandra and Edward Meyer Cancer Center
Mark A Rubin
Mark A RubinEnglander Institute for Precision Medicine, Weill Cornell Medicine and New York-Presbyterian Hospital
Mark A Rubin
Mark A RubinSandra and Edward Meyer Cancer Center
David S RickmanEnglander Institute for Precision Medicine, Weill Cornell Medicine and New York-Presbyterian Hospital
David S Rickman
David S RickmanSandra and Edward Meyer Cancer Center
  • 1 - 25

Datasets

Release 1.2